PDF(Pubmed)
Abstract：
UNASSIGNED: Anaemia is frequently observed in patients with cirrhosis and was identified as a predictor of adverse outcomes, such as increased mortality and occurrence of acute-on-chronic liver failure. To date, the possible effects of iron supplementation on these adverse outcomes are not well described. We therefore aimed to assess the role of iron supplementation in patients with cirrhosis and its capability to improve prognosis.
UNASSIGNED: Laboratory diagnostics were performed in consecutive outpatients with cirrhosis admitted between July 2018 and December 2019 to the University Hospital Essen. Associations with transplant-free survival were assessed in regression models.
UNASSIGNED: A total of 317 outpatients with cirrhosis were included, of whom 61 received a liver transplant (n = 19) or died (n = 42). In multivariate Cox regression analysis, male sex (hazard ratio [HR] = 3.33, 95% CI [1.59, 6.99], p = 0.001), model for end-stage liver disease score (HR = 1.19, 95% CI [1.11, 1.27], p <0.001) and the increase of haemoglobin levels within 6 months (ΔHb6) (HR = 0.72, 95% CI [0.63, 0.83], p <0.001) were associated with transplant-free survival. Regarding the prediction of haemoglobin increase, intake of rifaximin (beta = 0.50, SD beta = 0.19, p = 0.007) and iron supplementation (beta = 0.79, SD beta = 0.26, p = 0.003) were significant predictors in multivariate analysis.
UNASSIGNED: An increase of haemoglobin levels is associated with improvement of transplant-free survival in patients with cirrhosis. Because the prediction of haemoglobin increase significantly depends on rifaximin and iron supplementation, application of these two medications can have an important impact on the outcome of these patients.
UNASSIGNED: Anaemia is very common in patients with cirrhosis and is known to be a predictor of negative outcomes, but little is known about the effect of iron substitution in these individuals. In our cohort, increase of haemoglobin levels improved transplant-free survival of patients with cirrhosis. The increase of haemoglobin levels was mainly induced by iron supplementation and was even stronger in the case of concomitant use of iron and rifaximin.
UNASSIGNED: UME-ID-10042.
UNASSIGNED: Laboratory diagnostics were performed in consecutive outpatients with cirrhosis admitted between July 2018 and December 2019 to the University Hospital Essen. Associations with transplant-free survival were assessed in regression models.
UNASSIGNED: A total of 317 outpatients with cirrhosis were included, of whom 61 received a liver transplant (n = 19) or died (n = 42). In multivariate Cox regression analysis, male sex (hazard ratio [HR] = 3.33, 95% CI [1.59, 6.99], p = 0.001), model for end-stage liver disease score (HR = 1.19, 95% CI [1.11, 1.27], p <0.001) and the increase of haemoglobin levels within 6 months (ΔHb6) (HR = 0.72, 95% CI [0.63, 0.83], p <0.001) were associated with transplant-free survival. Regarding the prediction of haemoglobin increase, intake of rifaximin (beta = 0.50, SD beta = 0.19, p = 0.007) and iron supplementation (beta = 0.79, SD beta = 0.26, p = 0.003) were significant predictors in multivariate analysis.
UNASSIGNED: An increase of haemoglobin levels is associated with improvement of transplant-free survival in patients with cirrhosis. Because the prediction of haemoglobin increase significantly depends on rifaximin and iron supplementation, application of these two medications can have an important impact on the outcome of these patients.
UNASSIGNED: Anaemia is very common in patients with cirrhosis and is known to be a predictor of negative outcomes, but little is known about the effect of iron substitution in these individuals. In our cohort, increase of haemoglobin levels improved transplant-free survival of patients with cirrhosis. The increase of haemoglobin levels was mainly induced by iron supplementation and was even stronger in the case of concomitant use of iron and rifaximin.
UNASSIGNED: UME-ID-10042.
摘要：
未经证实：肝硬化患者常出现贫血，并被确定为不良结局的预测因子。如死亡率增加和慢性急性肝衰竭的发生。迄今为止,补充铁对这些不良结局的可能影响没有很好的描述.因此，我们旨在评估铁补充剂在肝硬化患者中的作用及其改善预后的能力。
UNASSIGNED：对2018年7月至2019年12月在埃森大学医院收治的肝硬化连续门诊患者进行了实验室诊断。在回归模型中评估与无移植存活的关联。
UNASSIGNED：共纳入317名肝硬化门诊患者，其中61人接受了肝移植（n=19）或死亡（n=42）。在多元Cox回归分析中，男性(危险比[HR]=3.33，95%CI[1.59，6.99]，p=0.001),终末期肝病评分模型（HR=1.19，95%CI[1.11，1.27]，p<0.001）和6个月内血红蛋白水平的增加（ΔHb6）（HR=0.72，95％CI[0.63，0.83]，p<0.001）与无移植生存率相关。关于血红蛋白增加的预测，利福昔明的摄入(β=0.50,SDβ=0.19,p=0.007)和铁补充剂(β=0.79,SDβ=0.26,p=0.003)是多变量分析中的显著预测因子.
UASSIGNED：在肝硬化患者中，血红蛋白水平的升高与无移植生存率的改善有关。因为血红蛋白增加的预测显著依赖于利福昔明和铁的补充，这两种药物的应用会对这些患者的预后产生重要影响。
UNASSIGNED：贫血在肝硬化患者中非常常见，已知是阴性结果的预测因子，但是对这些个体的铁替代作用知之甚少。在我们的队列中，血红蛋白水平升高可改善肝硬化患者的无移植生存率.血红蛋白水平的增加主要是由铁补充引起的,并且在同时使用铁和利福昔明的情况下甚至更强。
未经评估：UME-ID-10042。
UNASSIGNED：对2018年7月至2019年12月在埃森大学医院收治的肝硬化连续门诊患者进行了实验室诊断。在回归模型中评估与无移植存活的关联。
UNASSIGNED：共纳入317名肝硬化门诊患者，其中61人接受了肝移植（n=19）或死亡（n=42）。在多元Cox回归分析中，男性(危险比[HR]=3.33，95%CI[1.59，6.99]，p=0.001),终末期肝病评分模型（HR=1.19，95%CI[1.11，1.27]，p<0.001）和6个月内血红蛋白水平的增加（ΔHb6）（HR=0.72，95％CI[0.63，0.83]，p<0.001）与无移植生存率相关。关于血红蛋白增加的预测，利福昔明的摄入(β=0.50,SDβ=0.19,p=0.007)和铁补充剂(β=0.79,SDβ=0.26,p=0.003)是多变量分析中的显著预测因子.
UASSIGNED：在肝硬化患者中，血红蛋白水平的升高与无移植生存率的改善有关。因为血红蛋白增加的预测显著依赖于利福昔明和铁的补充，这两种药物的应用会对这些患者的预后产生重要影响。
UNASSIGNED：贫血在肝硬化患者中非常常见，已知是阴性结果的预测因子，但是对这些个体的铁替代作用知之甚少。在我们的队列中，血红蛋白水平升高可改善肝硬化患者的无移植生存率.血红蛋白水平的增加主要是由铁补充引起的,并且在同时使用铁和利福昔明的情况下甚至更强。
未经评估：UME-ID-10042。
